Skip to main content
. 2019 Nov 20;22(5):684–693. doi: 10.1093/neuonc/noz222

Table 4.

Progression-free survival, median OS, and survival at 12 and 24 months (95% CI) at the time of long-term follow-up analysis (237 events observed)

n Median PFS Median OS 12 mo OS 24 mo OS
Depatux-M + TMZ 88 2.7 (2.0, 3.8) 9.6 (7.4, 11.8) 39.7 (29.4, 49.7) 19.8 (12.2, 28.8)
Depatux-M 86 1.9 (1.9, 2.2) 7.9 (6.1, 8.7) 26.7 (17.9, 36.4) 10.0 (4.8, 17.6)
Lomustine or TMZ 86 1.9 (1.8, 2.0) 8.2 (5.9, 9.5) 28.2 (19.1, 37.9) 5.2 (1.7, 11.7)